Ladies and gentlemen, thank you for standing by, and welcome to the Q3 AMETEK Earnings Conference Call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Investor Relations, Kevin Coleman.
Thank you, Andrew. Good morning, and thank you, everyone, for joining us for AMETEK's Q3 2020 earnings conference call. With me today are Dave Zapico, Chairman and Chief Executive Officer and Bill Burke, Executive Vice President and Chief Financial Officer. AMETEK's 3rd quarter results were released earlier this morning and are available on market systems and in the Investors section of our website. This call is also being webcasted and can be accessed on our website.
The webcast will be archived and made available on our site later today. During the course of today's call, we will make forward looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC, including in our 10 Q, which we filed later today. AMETEK disclaims any intention or obligation to update or revise any forward looking statements. Any references made on this call to 2019 or 2020 results will be on an adjusted basis, excluding after tax acquisition related intangible amortization and also excluding the gain from the sale of Reading Alloys in the Q1 of 2020 and the realignment charge taken in the Q1 of 2020.
Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website. We'll begin today's call with prepared remarks by Dave and Bill and then open it up for questions. I'll now turn the meeting over to Dave.
Thank you, Kevin, and good morning, everyone. AMETEK delivered a strong 3rd quarter despite ongoing challenges presented by the COVID-nineteen pandemic. While sales continued to be impacted by the pandemic, the demand environment showed solid improvements from the Q2 as customers returned to work and travel restrictions began to slowly ease. In addition, our businesses delivered outstanding operating performance, allowing us to expand margins, generate excellent cash flow and drive earnings ahead of our expectations. I would like to thank our employees who are managing exceptionally well through this pandemic, overcoming both personal and professional challenges to provide essential products and services to our customers.
I continue to be impressed by the strength of our workforce and the dedication to our mission of solving our customers' most complex challenges. We remain vigilant and focused on our employees' safety. Our site and country level pandemic coordinators are doing an excellent job adapting to the shifting guidelines provided by the CDC and local health and safety agencies. The flexibility our teams have shown in implementing new processes and protocols to ensure a safe working environment has been excellent. Now let me turn to our results for the quarter.
3rd quarter sales were $1,130,000,000 down 12% compared to the Q3 of 2019. Organic sales were down 14%, with the recent acquisitions contributing 5 points to growth, the divestiture of Redding Alloys a 3 point headwind and foreign currency adding 1 point. As expected, our commercial aerospace business, which is less than 10% of the overall company, experienced the largest impact from COVID with sales down approximately 35% versus the prior year. Our businesses continue to drive operational excellence initiatives to help mitigate demand weakness. These efforts led to excellent operating results in the quarter.
3rd quarter operating income was $270,700,000 and operating margins were a record 24%, up 40 basis points compared to last year's Q3, while decremental margins were an impressive 20% in the quarter. EBITDA in the 3rd quarter was $332,000,000 and EBITDA margins were a record 29.5%, up 2 10 basis points over last year's comparable period. This led to earnings per diluted share of $1.01 down just 5% compared to the Q3 of 2019. Furthermore, our business has generated a strong level of cash flow. Operating cash flow in the quarter was $310,000,000 and free cash flow conversion was an impressive 146 percent of net income.
Next, let me provide additional details at the operating group level. Our Electronic Instruments Group performed very well in the quarter despite end market weakness, delivering outstanding operating performance, resulting in strong margin expansion. Sales in the Q3 for EIG were $748,400,000 down 8% from the comparable period in 2019. As expected, we saw solid and widespread sequential sales improvements from the 2nd quarter. Organic sales were down 15% year over year, with the acquisitions of Gatan and Intellipower contributing 6 points and foreign currency contributing 1 point.
Commercial Aerospace remains the largest driver of organic sales weakness in EIG. EIG's 3rd quarter operating income was $203,700,000 and operating margins were an impressive 27.2%, up 30 basis points compared to the same quarter last year. Our electromechanical group also saw sequential sales improvement and mitigated a weak demand environment with solid operating performance. EMG sales were $378,600,000 down 18% from last year's Q3, driven in part by the impact of the Reading Alloys divestiture. Organic sales were down 13%, with the divestiture an 8 point headwind, the acquisition of PDT adding 2 points and foreign currency adding 1 point.
EMG's operating income was $84,300,000 and operating margins were solid at 22.3 percent for the quarter. Let me comment briefly on end market dynamics for some of our businesses. Overall, we saw solid sequential sales improvements across all markets in the Q3. We expect continued sequential improvements in the 4th quarter for all businesses other than commercial aerospace, where we expect largely flat conditions sequentially. Our strongest market remains defense, where we continue to be well positioned with content across a wide range of important defense platforms.
We are also very well positioned within our medical and healthcare businesses, although they experienced a delay in the return of elective procedures during the Q3, which offset solid COVID driven demand. And our most challenged markets remains commercial aerospace, remain cautious of a trajectory of a recovery given the uncertainty caused by COVID-nineteen. Given the uncertain and challenging end market dynamics, our businesses remain highly focused on driving operational excellence initiatives, both structural and temporary, to manage top line weakness while assuring we maintain our investments in key growth initiatives across the company. AMETEK's asset light operating model provides us with the flexibility to do both. Our ability to expand margins and generate strong levels of cash flow during this pandemic is evidence of the strength of our operating model.
In the Q3, we generated $70,000,000 in total cost savings, which was at the high end of our expectations, with $40,000,000 in structural savings and $30,000,000 in temporary cost reduction savings or structural savings, while temporary savings will be reduced from the 3rd quarter levels as we add back additional temporary costs during the quarter. As a result, we expect approximately $55,000,000 in total cost savings in the 4th quarter, with $45,000,000 in structural and $10,000,000 in temporary cost savings. And for the full year, we expect approximately $230,000,000 in total cost savings with $140,000,000 in structural savings and $90,000,000 in temporary savings. Our businesses continue to implement new and innovative ways to reach our customers around the world and in new markets. Through virtual meeting platforms, augmented reality product demonstrations and service and enhanced digital marketing initiatives, our businesses have adapted quickly to the new landscape.
Seeing our businesses adopt these new ways of doing business quickly and effectively has been very impressive. Our businesses are also collaborating across platforms. As an example, AMETEK Land and AMETEK Rolland recently partnered together to help support Rolland's reopen school safely campaign for their TelecenterU solution. Rolland is a leading provider of critical communications, workflow and safety solutions for hospitals and schools. Their TelecenterU solution connects classrooms and educational facilities to district offices for emergencies, event management and everyday communications.
As I mentioned on our last earnings call, AMETEK Land, a leading manufacturer of non contact temperature measurement solutions, recently developed their new Viralurp3 system for rapid detection of elevated skin temperatures at points of entry to various facilities, including schools. Through this collaborative effort, Rollins was able to incorporate LAN's Viralurp3 technology into their telecenter use solution that their customers safely reopen their schools by allowing for temperature screening of students and faculty. In return, AMETEK Land will reach thousands of new potential customers through Rollins' well established network of school districts. The result was a valuable solution for our customers. Congratulations to the AMETEK and the AMETEK Rolland team for the success on this project.
We're also finding ways to support our customers through new product innovation. Throughout the pandemic, we continued to invest meaningfully in our research and development initiatives, and we're seeing great success from these efforts. Our vitality index, which measures the amount of sales generated from new products introduced during the last 3 years, was very strong at 25% in the quarter. During the quarter, CreoForm, a worldwide leader in 3 d measurement solutions, unveiled its R Series 3 d scanning solution that's designed for automated dimensional quality control applications. The suite of R Series solutions includes the new robot mounted MetraSCAN 3 d scanner with the QVAR, a turnkey industrial measuring cell that is designed to be integrated into factories for at line inspections.
Together, this solution provides customers with much faster cycle times, more accurate and repeatable results, higher resolution and operational simplicity to increase productivity by measuring more dimensions on more parts without compromising on accuracy. Congratulations to the CreoForm team for launching this outstanding new solution. Now shifting to acquisitions. While deal flow during the 2nd and third quarters has been impacted by the pandemic, we are starting to see a healthy pickup in activity. Our pipeline is strong and conversations with acquisition targets are accelerating.
As Bill will highlight in a moment, over the last two quarters, we have further strengthened our balance sheet and liquidity position and remain poised to deploy significant capital on strategic acquisitions. We will remain active yet disciplined in our acquisition process. We continue to focus on acquiring niche technology leaders with attractive growth profiles with opportunities for us to add value commercially and operationally. Now turning to our outlook for the remainder of the year. While the global economy continues to present challenges and uncertainties, visibility has improved across most markets.
As a result, we're providing guidance for the Q4. Overall sales in the 4th quarter are expected to be down high single digits with a similar level of organic sales decline. Diluted earnings per share are expected to be in the range of 1 dollars to $1.04 down 4% to 7% versus the prior year. 4th quarter decremental margins are expected to remain solid in the low 20s. To summarize, our businesses delivered a solid quarter in a difficult AMETEK continues to manage this global crisis well through the proven strength of the AMETEK growth model and with a talented workforce.
Our cost mitigation efforts have allowed the company to weather this ongoing storm, and we are confident that we will overcome these challenges with a bright future. I'll now turn it over to Bill Burke, who will cover some of the financial details for the quarter, then we'll be glad to take your questions. Bill?
Thank you, Dave. I'd like to echo Dave's comments on the quarter as we saw outstanding operating performance driven by the tremendous efforts of our team in a very challenging economic environment. Let me provide some additional financial highlights for the quarter. 3rd quarter general and administrative expenses were down $4,500,000 compared to the same period of 2019, primarily due to lower compensation costs and other discretionary spending cuts. As a percentage of sales, general and administrative expenses were 1.5% of sales in the quarter, down from 1.7% last year.
The effective tax rate in the 3rd quarter was 17.5%, down from 19.5% in the same period last year. The lower tax rate in the quarter was due to return to provision adjustments and a lower tax rate on foreign earnings. For 2020, we now expect our effective tax rate to be between 19% 19.5%. And as we've stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively, from this full year estimated rate. Operating capital and working capital was an impressive 17% in the 3rd quarter, down sequentially from the 2nd quarter's 19.6% on outstanding working capital management.
Capital expenditures in the quarter were $10,000,000 We now expect full year capital expenditures to be approximately $80,000,000 which is $5,000,000 higher than our full year expectations last quarter as we are investing in incremental growth opportunities. Our full year capital expenditures estimate remains below our initial expectations to start the year of $100,000,000 Depreciation and amortization expense in the quarter was $63,000,000 For the full year, we expect depreciation and amortization to be approximately $255,000,000 which includes after tax acquisition related intangible amortization of approximately $117,000,000 or $0.51 per diluted share. Our businesses continue to generate strong levels of cash flow despite the challenges presented by the pandemic. Operating cash flow in the quarter was $310,000,000 free cash flow was $300,000,000 and free cash flow conversion was excellent at 146 percent of net income. Total debt at the end of the quarter was $2,800,000,000 up slightly from $2,770,000,000 at the end of 2019 and down $68,000,000 from the end of the second quarter.
Offsetting this debt is cash and cash equivalents of $1,300,000,000 Our gross debt to EBITDA ratio at This ratio was comfortably below our debt covenants of 3.5 times, and our net debt to EBITDA ratio was 1.1 times atquarterend, which improved by 2.2 turns in the quarter. We remain well positioned to manage this ongoing economic downturn with approximately $2,300,000,000 in liquidity to support our operations and growth initiatives. This includes approximately $1,000,000,000 in available revolver capacity. As we've highlighted on previous calls, AMETEK has a robust balance sheet with no material debt maturities due until 2023. In summary, our businesses continue to manage through the pandemic exceptionally well, delivering strong operating results and high levels of cash flow.
The dedication of our world class workforce to serving our essential customers has truly been impressive. We remain well positioned to manage ongoing economic challenges while investing in our long term growth initiatives. Kevin? Thank you, Bill. Andrew, we're ready to take questions.
Certainly. And our first question comes from the line of Matt Summerville with D. A. Davidson.
Good morning, Matt.
Hey, Dave. I was wondering if you can maybe start by doing your more detailed walk through on the businesses, please?
Sure. I'll start with the Process business. Overall sales for Process were down mid single digits in the quarter. We had the contributions from the Gatan acquisition and they were offset by an organic sales decline and it was in line with AMETEK's overall organic sales decline. We saw sequential improvements in sales during the quarter with this improvement being widespread across our process businesses.
Our Kamika and Zygo businesses had solid quarters driven in part by their exposures to research and semiconductor markets. They did very well. And we expect continued solid sequential improvements in sales for process during the Q4. I'll go into Aerospace next. Both overall and organic sales for our entire A and D business were down mid teens in the quarter, showing nice sequential growth from the Q2.
Similar to the Q2, there was a meaningful difference in performance between our defense and commercial aerospace businesses. Our defense businesses continued to see solid demand with sales up low double digits on a percentage basis versus last year, while the commercial aerospace businesses were down about 35% versus last year. Looking ahead to the Q4, we expect demand to maintain to be relatively flat sequentially versus the Q3 as the broad commercial aerospace market continues to adjust to the uncertain demand environment due to COVID-nineteen. And next, our Power and Industrial market segment. Overall sales for Power and Industrial were down low double digits in the 3rd quarter with contributions from Intellipower being offset by a mid teens organic sales decline.
Demand levels in the 3rd quarter improved nicely from the 2nd quarter, and we expect sequential improvements again in the 4th quarter. And finally, for our Automated and Engineered Solutions market segment, organic sales in the 3rd quarter for A and ES were down mid teens on a percentage basis. We saw modest sequential improvements across these businesses in the 3rd quarter as we had expected with applications tied to medical markets performing well. We also saw a return to growth in China for our Automation and Engineered Solutions business in the quarter. And as with the other sub segments, we expect sequential improvements across both our automation and engineered solutions businesses in the Q4.
That's a walk around the company, Matt.
Thanks, Dave. And then as my follow-up, can you comment on what your price realization was in Q3? And what you are looking for in terms of sourcing savings for the full year? Thank you.
Yes. I think the I'll go with the price first. We're very pleased to see our pricing held up well. Q3 was similar to Q2. We achieved about 1.5 of price across our entire business.
Total inflation and the impact of tariffs was about 1 point, so we had 50 basis points of positive spread added to margins. And your second question was on sourcing savings. That we consider that part of structural savings and it was about $60,000,000
Thank you. And our next question comes from the line of Deane Dray with RBC Capital Markets.
Yes. The one point though to finish, it was $60,000,000 for the year to Matt. And go ahead, Deane.
Sure. Thanks. Good morning, everybody.
Thanks.
Great to see you guys are back in the quarterly guidance business because that does speak to your earnings visibility. So first question is kind of related to this visibility. If you could take us through the cadence of the months in the quarter organically and maybe how October month to date has looked? And let's start there, please.
Sure. In terms of orders in Q3, it was pretty typical trend for us with September being the strongest month of the quarter. In fact, it was our strongest month since I believe February back in Q1 when we started to really feel the impact of the virus. That's orders. In terms of sales, September again was our highest month of the quarter and the highest month of the year so far.
And in terms of October, obviously, it's not completed yet, but it looks good. Orders are trending well and is supportive of our guide in Q4, which shows solid sequential improvement.
So did you see in the months that sequential improvement consistent through the quarter?
We saw sequential improvements in orders. In sales, I believe, August was a bit of an outlier, but August is always tricky for us. So in general, it was a trend upward with September the highest in both sales and in orders.
Great. And then just kind of bridge this degree of confidence in the sequential improvement, how this translates into your confidence in restoring guidance?
Yes. I think the confidence is really based on us becoming more confident with our ability to live with the virus. And we got visibility in our markets. We're seeing consistent improvement and consistent engagement with customers across all of our markets. And we just got to the point where we were comfortable with giving guidance.
Our guidance range is a little bit wider than it typically is and that takes into account some of the uncertainty for the Q4, but we just got comfortable because our businesses are operating in a good rhythm and it builds the level of confidence with us.
Great. And then just my last question, not to oversimplify your mix and with respect to how you in the last question, Matt's question, you gave and highlighted those businesses. But if I thought about AMETEK in the strength of your medical and defense, those are probably and then the weakest, which is more secular, it's not execution, we get that. And actually, the commercial business, you've outperformed a number of your peers in that space, in this market. So, but the two sides of this medical defense, how they do versus the oil and gas and commercial aero on the other side?
That's a great question. One way to think about it is, if I take the 2 most challenged markets out, the commercial aerospace and the oil and gas, sales were down approximately 10%. And another way to think about that is our defense showed strong growth in the 3rd quarter, up mid teens. Our healthcare business was just slightly down because of the we had COVID related demand that was strong, but we had people weren't going to hospitals and getting surgical procedures. So that was off a little bit, but the combinations of both the defense and medical was clearly our strongest and that was about flat.
Terrific. And just a quick clarification. When you said flat 4Q for aero, was that commercial aero and defense or was it combined? Yes. So sequentially,
we're saying it's going to be flat and that's both for military and commercial aerospace.
Got it. That's really helpful. Thank you.
Thank you. And our next question comes from the line of Scott Graham with Rosenblatt Securities.
Hi, Scott.
Hey, good morning. Well done again.
Thank you.
I do have a question first on, I think, an area that you might be most proud of this quarter, operating working capital. What did you do there to push that percentage down as much as you did? What happened?
Got it. The first comment is that's one of the hallmarks of AMETEK is our we think about working capital as being very you have to run businesses where you're efficient with working capital. And there are some elements that really over performed and I'll let Bill comment on that.
Yes. I think what you saw was our receivables performance has been fantastic. Our businesses have really done a great job staying close to our customers and understanding that pushing for payment. Our receivables were down to 46 days on a DSO basis, which is as low as it's been in quite a while. So I think the teams did a fantastic job there.
And then the other thing, it's a little more difficult, especially when sales are declining as rapidly as they did earlier in the year is getting your supply chains realigned to that level of demand, and they did a great job with that as well. And I think you saw that play out in the Q3. So I think those two things in combination really enabled us to reduce that working capital percentage to 17%, and the teams have just done a fantastic job on that around the company.
That's great. Thank you, Bill. Now here's another one. The $90,000,000 of expected full year temporary cost reductions,
a lot of
companies are saying, hey, not all of that comes back. What is your view on that for 2021 at this point? How much of that comes back? How much of it is maybe permanent?
Yes. The first point I'd make is the temporary cost savings will be at a run rate of about $10,000,000 in the 4th quarter. The second point is related to next year, we were in a situation we have to sit down with all of our teams, our budgeting processes in November. It's a bottoms up comprehensive planning process for each business unit. They're going to look at growth in each of their markets, customer plans, competitive dynamics, investments, opportunities, capital projects, cost reduction.
And part of that discussion is going to be how fast the temporary costs are going to come back and what the impact is year over year. At a high level, travel is a part of that and it's going to come back slowly through the year, but some of the costs have already been restored. So we really don't have a detailed plan on that next year because we haven't done our budget yet. We start that process in November. But that's how I think about it.
Got it. Last question. Thank you for that. On the M and A pipeline, obviously, you have a much broader swath of businesses today than you did even 2 or 3 years ago, particularly I look at Gatan and how you've gotten even more into the scientific markets. Could you give us maybe something a little bit more granular, Dave, on what you're looking for?
And I know competitively, you got to be careful there. But I'm assuming that medical scientificresearch would be really kind of at the top of the list for things you're looking for. Could you comment on that?
Yes, I think that's an area that we're definitely looking at. I mean, it's broad based. As you know, we have a decentralized business model and we get acquisition plans rolled up through our businesses through an adjacency process. And we're looking at that all parts of the business in all areas and we're seeing an uptick in opportunity uptick in discussions. But they could come from all parts of our business, but the area that you highlighted is a particularly interesting one to us.
Very good. Thank you. Good job.
Thank you, Scott. Thank you. And our next question comes from the line of Ivana Delevska with Gordon Haskett.
Hello, Ivana.
Good morning. Good morning, guys. So just wanted to ask what percent of your portfolio, maybe excluding aero and defense and medical is levered to CapEx? And what are you seeing in those CapEx levered businesses?
Yes. Most of the products that we sell are at a price range that could be considered both OpEx or CapEx. So we really don't segment it that way. But certainly, the when you think about the big projects and the big project businesses in our oil and gas business and our metals business and some of the heavier industries are delayed right now, but the operating expenditures are continuing. So I really don't have a percentage to give you, but that's how we think about it.
And then in terms of the CapEx levered businesses, are those like down significantly more than the rest, would you say?
No. In fact, our in the research market for Kamika, they're selling $1,000,000 $3,000,000 tools and that was one of the businesses that I highlighted in process that I talked about in our so that's not the case. I mean, that's a university market or a research market, very expensive. The key there is that we have the best products and we're the only one in the world that makes an atom probe and we have a unique SIMS capability. So people save, they budget for our products and we've built products and they deliver them.
So in Kamika, which is a CapEx market for us, it had one of their best quarters. So it's really dependent on customer dynamics.
Got it. Thank you very much.
Okay.
Thank you. Your next question comes from the line of Nigel Coe with Wolfe Research.
Thanks. Good morning and thanks for the question. So Dave, I want to go back to the aerospace, down 35%. It's a steep decline for sure, but compared to sort of down 50% to 60% we've seen from some of the other suppliers into that market. So I'm curious, would there be a reason why your decline would be significantly decoupled from what we see in the industry?
I'm thinking about maybe programs or other factors because that doesn't sound like it, but that's actually a pretty good performance.
Yes. I mean, it's it was a good performance. You remember, we thought we were going to be down in the mid to high 40s and we ended up down 35% in the commercial aerospace. Our teams did an excellent job. When you look at the different sub segments, Steve, 3rd party aftermarket and the commercial OEM ended up being down similar with business jet and we thought that business jet would be higher and the 3rd party aftermarket and the commercial OEM will be lower and those 2 sub segments perform better.
But that's as much of backlog and things like that commercial is finding a bottoms. There are many variables including government support, airline capacity decisions, obviously the confidence that are flying public and we thought about our business sequentially that's the only part of our business we think will not improve. So definitely a better quarter. I can't comment on how the performance of other companies because I really don't know it. But I know our teams did a good job on shipping product and as a negative 35%, pleased with the performance, as strange as that sounds.
Yes, right. That business is definitely getting better. And then just on the structural costs, you gave some great detail there. And I think you said $45,000,000 of costs during 4Q. Is that a full run rate?
So as we go into 2021, are we looking at maybe, I don't know, dollars 40,000,000 or so of kind of like carryover benefits into 'twenty one?
Yes. First of all, Nigel, it's $55,000,000 of savings in Q4 and $45,000,000 of it is structural and $10,000,000 of it is temporary. And I'm going to give you a there's a $50,000,000 carryover from the restructuring that we did earlier in the year. But in terms of getting into any specifics, I'm going to not answer the question for next year. And our budgeting process is going to be in November.
And really, there's a lot of discussion on cost reduction, investments and the temporary costs that are going to come back and that all goes into a mix. It will be a pretty complex budgeting process this year With the pandemics, there are some extra variables in it. So, I'm not going to comment on what the savings will be for next year.
So it sounds like you're still maybe contemplating a different action for 4Q and it's kind of like maybe set up for 2021, would that be fair?
No, I don't think so. But we're going to go through our budgeting processes and something they can't come out of there, but we don't have anything planned in Q4. Okay. Thanks, Dave.
Thank you. And our next question comes from the line of Christopher Glynn with Oppenheimer.
Thanks. Good morning, guys. Hope all is well. Good morning, Chris. So, just wondering if in the current environment where some smaller companies might be concerned about global dynamics, supply chain, trade, etcetera, if you're picking up on any new motivations by sellers, including some you've tracked and courted for some years?
Yes. I think there is some activity out there where people are anticipating possibly a tax rate change. So there is some people that are have their businesses out there as part of the uptick in pipeline opportunities. And in terms of the overall uncertainty in the global environment, if you're a smaller owner of a company that has all these dynamics in terms of COVID and geopolitical issues and issues with China, you're certainly a little unsettled. And we've known those people for years and we're certainly having discussions on them in terms of what the right time for them to sell their businesses.
Okay. And any changes in the competition for deals that you're interested in seeing?
I would say no competition change that's noticeable. It's been about the same for the last couple of years.
Great. Thank you.
Thank you, Chris.
Thank you. And our next question comes from the line of Andrew Obin with Bank of America.
Hey, good morning guys.
Good morning, Andrew. Good morning.
Just a couple of people actually asked me, did I miss did you guys actually give us actual orders in the Q3? You usually do that.
Yes, I
can do that. Our overall orders were minus 8%, our organic orders were minus 12% and our book to bill was 1.01.
Okay. That was easy. And then the second question just I'll ask on elective procedures. I think most of your competitors sort of said that elective surgery is back to 90%, 95% level pre COVID. Are you just has that been your experience and what are you seeing on elective procedures into Q4?
Yes. I think elective procedures for us, we think is going to stay at a reduced level until next year is that we're hearing from customers. So we think we'll have another quarter in Q4 of some kind of reduced elective procedures and then it will recover next year. And I anticipate working off backlog and there's less demand with COVID. So that market will correct itself as time goes on.
But your experience is consistent sort of with the data that I cited that your competitors are citing, right? Yes.
I'm not sure what the competitors have cited, but we're down a bit and the numbers that you put out there 90% or 95% kind of makes sense.
Okay. And just to ask Iwona's question in a slightly different way. On the way up as IP recovers, what kind of revenue leverage to IP should we be thinking for your portfolio ex aero and maybe ex healthcare?
Right. That's something we're going to talk about with our businesses, but historically AMETEK has recovered very well from significant downturns. And we're seeing the improvements in Q3 versus Q2. We're anticipating seeing it in Q4 versus Q3. And historically, we've really performed well in uptick.
So we have a mid and long cycle business and we're seeing good improvements. And what you're seeing now is a short cycle activities picking up. So that should bode well for the future, but we're going to go through our budgets and figure everything out.
Thank you so much.
Thank you, Andrew.
Thank you. And our next question comes from the line of Brett Linzey with Vertical Research.
Hey, good morning all. First question just on defense and medical. First on the defense side, very strong 2020, continues to look pretty good here. What is your visibility in that business next year based on wins or platforms you're on? Clearly a tough comp, but can you see that growing still next year?
And then on the medical side, any identifiable COVID related opportunities that you could point to or even quantify that could pop up here over the coming months?
Yes. The first question is, I'm really not going to comment on the military demand environment next year, but the spending pattern, those things are relatively healthy and we'll see what the political environment brings, but usually those changes occur slowly over time. So you think that the overall spending environment will be supportive next year. And we are quoting activity shows that. In terms of the COVID related products, I mean, the first thing I pointed to is the land temperature measurement, so we're doing body temperature scanning.
When I came in to work today, I went through the LAN system. It's very quick, easy, efficient and measures body temperature. The other things that are happening in our automation business, there's a lot of COVID testing devices that require sample automation, movement of samples very precisely through testing. The demand in that business is very strong. We're also seeing some demand for temporary setups in hospital type situations with our Rolland Healthcare businesses.
So we're really seeing some pockets of improved demand and that's built into the overall story.
Got it. That's great. And then just in terms of the geographic complexion, could you maybe give
us a little more color what
sales or order rates? And then I'm actually curious specific on Europe in October where the lockdown chatter and maybe even enactment was starting to percolate a little bit? Did you see a slowing kind of late in October in Europe? Thanks.
Yes. I'll take the second question first. I mean our orders for October are very good. They're in line with what we are expecting, and we're seeing no geographical problems at this point. In terms of the Q3, the geographical Q3, we had positive sequential trends across all geographies with Europe and U.
S. Remaining the most challenged. So the U. S. Was down, I think, 13%, broad based weakness.
Europe was down 20% on broad based weakness. Asia was down mid single digits. We had a good strength in EMG in China and China was positive at plus 3 for us. So but all geographies improved sequentially.
Got it. Thanks, Dave.
Appreciate it. Thank you, Brad.
Thank you. Your next question comes from the line of Joseph Giordano with Cowen.
Hey, good morning. This is Robert.
Hey, good morning. It's Robert in for Joe this morning. Thanks for taking my question. My graph has been covered. I guess just a quick one on the structural and variable cost for 4Q.
Is there any is that pretty evenly split between EIG and EMG? Is there any way to think about it?
Yes, it is. It is pretty well split between the 3 groups. EIG is a little bit higher because of the relative size of it. It's split based on volume.
Okay, great. And then can you provide another update on Gatan's performance so far and how that's progressing versus expectations and synergies into
next year? Yes. I mean we met our year 1 profitability targets. We're going to be reviewing that with our Board next week. Next week.
So very good 1st year. Team did an excellent job. We had we were helped by COVID related sales about half of that business is life sciences. And we also announced the combining of Gatan with our EDX business in similar markets, so we drove excellent synergy. So very positive and the K3 camera helped us solve some of the COVID related problems being the first camera to structure the virus.
So all very good and the people at Gatan are very proud of that. Okay.
Thank you. And our next question comes from the line of Andrew Buscaglia with Berenberg.
Good morning, guys.
Good morning, Andrew.
So David, you talked about you reinstated quarterly guidance and you mentioned visibility getting a little bit better, which is interesting. Some companies aren't willing to say that yet or hesitate into year end as still a lot of uncertainty. So I guess, where are you seeing across your space? Where are you feeling more comfortable? Obviously, some areas with by nature like military spending, you can have better visibility just all the time.
But I guess where do you get more comfortable saying that? And maybe is this coming from some sort of like conversations you're having with your customers?
Yes. That's a great question, Andrew. And when you think about it, we're getting better at living with the virus. Our customers are getting better at living with the virus. Our suppliers are getting better at living with the virus.
And there is an uptake in cases, especially in Europe and the Western U. S. And we're watching that closely. But we expect to continue to run as an essential business and our customers are essential customers and they're expecting to continue to run. So business activity levels are continuing to improve.
And even in Europe, when you have some increased lockdowns in certain degrees, essential businesses are still operating. So that's really the broader context that we use to reinstate guidance and talking with our teams, they're confident they can deliver their Q4.
Yes. That's fair. And you talked a lot about this quarter about some benefits from COVID and some COVID related products. I guess, it's hard you have a lot going on, on that side. I guess, how much of it do you think is sustainable demand into 2021?
I guess, I mean, how would you characterize sort of a temporary bump in demand related to those products versus something that might linger into next year and beyond?
Yes. As I said a couple of times, we are not going to talk about next year. We are going to work with our teams. But in general, we are seeing a pretty substantial improvement quarter to quarter and we will find out the details with our teams. But I would expect that improvement trend will continue into next year.
And as I've talked earlier in this call about AMETEK typically has responded positively to deep downturn. So we'll find out a lot. We don't know about the timing. And there may be some COVID related demand that falls off, but there's also going to be some demand that was impacted by COVID that's going to improve. So we'll figure that all out during our budgeting process.
Okay. All right. That's fair. Thanks, David.
Thank you.
Thank you. And our next question comes from the line of Michael McGinn with Wells Fargo.
Hey, guys. Mike on for Allison. Thanks for the question.
Hi, Mike. Hi, Mike. I
wanted to go back to the capital allocation discussion. So as you move into these heavy R and D industries with the bolt on acquisitions versus maybe more material and direct COGS Industries. Is there any discussion on the way you approach and report gross margin, which I believe differs from your peer set?
Yes. Our cost of sales includes engineering and that's historically how we've done that and we have not had a discussion recently of changing that.
Okay, fair enough. And then
I guess switching to some
of your end markets. I believe you have an automation and engineered solutions platform that was approaching $1,500,000,000 prior to the downturn. So I was curious what a near shoring or reshoring kind of player theme would look like for you guys in the businesses that would be most impactful for?
Yes. Automation is one of them. Automation did well in the Q3. It did better than our engineered services business and they are seeing that demand. They also saw good strength in China from that.
And when you think about the product that I talked about today from Priaform, that's all our product were for At Line Metrology. So our automation businesses and our instrumentation businesses are very well positioned to do to improve in an environment that includes reshoring. We have a lot of products that our customers use to make their manufacturing more efficient and more productive.
Some of those businesses have a higher vitality index than maybe the legacy AMETEK platform? I believe you said it was like 25% this quarter. Just is that where the R and D focus is now and going forward?
Yes. I think the R and D focus is EIG biased versus EMG and the vitality index is higher in those kind of businesses. So that would be a correct view from your viewpoint.
Okay. Appreciate the time. I'll pass it along.
Thank you.
Thank you. I will now turn the call back over to Kevin Coleman for any closing remarks.
Thank you, Andrew, and thank you, everyone, for joining our call today. And as a reminder, a replay of the webcast can be accessed in the Investors section of amatek.com. Thanks and have a great day.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.